DDInter1729 DDInter621
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Diflunisal
Diflunisal {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Treprostinil
Treprostinil {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaprozin
Oxaprozin {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac {u} (Compound) causes {v} (Side Effect) Alopecia
Alopecia {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Sulindac {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Diflunisal (Compound) and Diflunisal may lead to a major life threatening interaction when taken with Edoxaban
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is bound by Treprostinil (Compound) and PPARD (Gene) is upregulated by Treprostinil (Compound) and Treprostinil may lead to a major life threatening interaction when taken with Edoxaban
Sulindac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Edoxaban
Sulindac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Oxaprozin (Compound) and Oxaprozin may lead to a major life threatening interaction when taken with Edoxaban
Sulindac (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Sulindac (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Sulindac (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Edoxaban